Genetic Signatures Ltd. (AU:GSS)
ASX:GSS
Want to see AU:GSS full AI Analyst Report?
Top Page
Genetic Signatures Ltd.
(Sydney:GSS)
Select Model
Select Model
Rating:39Underperform
Price Target:
AU$0.06
▼(-74.17% Downside)
Action:Downgraded
Date:05/02/26
The score is driven primarily by weak financial performance—ongoing losses and negative cash flows outweigh the benefit of low leverage. Technicals also pressure the score, with the stock trading below all major moving averages and weak momentum. Valuation is further constrained by a negative P/E and no dividend yield provided.
Positive Factors
Proprietary 3base platform & assay menu
A proprietary 3base multiplex PCR platform and broad assay menu create durable competitive advantages: they drive recurring consumable demand, simplify lab workflows, and support commercial partners. This product-led model underpins sustained revenue potential as installed base grows.
Negative Factors
Persistent unprofitability
Consistent negative net, EBIT and EBITDA margins show the company is not yet converting revenue into profits. Persistent losses deplete reserves, necessitate external funding, and constrain strategic options until structural margin fixes are implemented.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary 3base platform & assay menu
A proprietary 3base multiplex PCR platform and broad assay menu create durable competitive advantages: they drive recurring consumable demand, simplify lab workflows, and support commercial partners. This product-led model underpins sustained revenue potential as installed base grows.
Read all positive factors
Genetic Signatures Ltd. (GSS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$15.22M
Dividend YieldN/A
Average Volume (3M)149.45K
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue Growth9.69%
EPS Growth52.31%
CountryAU
Employees117
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.05
Shares Outstanding227,138,820
10 Day Avg. Volume161,537
30 Day Avg. Volume149,454
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.65
Price to Sales (P/S)5.20
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.10Price Target Upside-58.33% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$18.20M
Genetic Signatures Ltd. Business Overview & Revenue Model
Company Description
Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of ...
How the Company Makes Money
GSS makes money primarily by selling molecular diagnostic test kits/assays that laboratories run on their PCR platforms, with revenue recognized from the supply of these consumable products as customers perform ongoing patient testing. A key reven...
Genetic Signatures Ltd. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.08M | 15.90M | 9.77M | 16.94M | 35.42M | 28.28M |
| Gross Profit | -12.87M | 7.78M | 4.31M | -12.74M | 7.21M | 4.27M |
| EBITDA | -15.38M | -16.08M | -19.82M | -13.14M | 4.70M | 3.22M |
| Net Income | -11.27M | -20.10M | -17.86M | -14.05M | 3.06M | 1.76M |
Balance Sheet | ||||||
| Total Assets | 49.04M | 54.63M | 67.29M | 49.08M | 59.65M | 54.05M |
| Cash, Cash Equivalents and Short-Term Investments | 29.87M | 31.30M | 36.25M | 16.35M | 36.90M | 30.12M |
| Total Debt | 653.00K | 791.00K | 1.22M | 0.00 | 34.00K | 399.00K |
| Total Liabilities | 4.95M | 4.54M | 6.18M | 6.16M | 4.85M | 4.71M |
| Stockholders Equity | 44.09M | 50.09M | 61.10M | 42.91M | 54.80M | 49.34M |
Cash Flow | ||||||
| Free Cash Flow | -10.67M | -13.19M | -14.91M | -20.55M | 6.82M | -784.00K |
| Operating Cash Flow | -9.60M | -12.29M | -10.12M | -12.45M | 9.81M | 4.20M |
| Investing Cash Flow | -13.57M | -24.30M | -4.79M | -8.09M | -2.99M | -4.98M |
| Financing Cash Flow | -455.00K | 7.79M | 34.81M | -23.00K | -101.00K | -190.00K |
Genetic Signatures Ltd. Technical Analysis
Negative
0.24
Price Trends
0.09
Negative
0.10
Negative
0.18
Negative
Market Momentum
>-0.01
Negative
41.34
Neutral
42.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GSS, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.09, and above the 200-day MA of 0.18, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 41.34 is Neutral, neither overbought nor oversold. The STOCH value of 42.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:GSS.
Genetic Signatures Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$51.74M | 23.69 | 72.82% | ― | 22.56% | 19.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$106.86M | -6.95 | -164.12% | ― | -14.85% | -41.04% | |
44 Neutral | AU$34.29M | -4.50 | -164.22% | ― | ― | 26.04% | |
41 Neutral | AU$41.87M | -5.48 | -476.27% | ― | ― | -142.39% | |
39 Underperform | AU$15.22M | -1.35 | -23.93% | ― | 9.69% | 52.31% | |
38 Underperform | AU$54.20M | -6.73 | -37.14% | ― | 4.66% | 12.39% |
* Healthcare Sector Average
AU:GSS
Genetic Signatures Ltd.
0.07
-0.34
-83.58%
AU:BDX
BCAL Diagnostics Limited
0.08
0.02
38.33%
AU:RHY
Rhythm Biosciences Ltd.
0.11
0.05
77.42%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.12
0.09
283.33%
AU:CTE
Cryosite Limited
1.06
0.32
43.24%
AU:IIQ
Inoviq Ltd
0.42
0.04
10.53%
Genetic Signatures Ltd. Corporate Events
Genetic Signatures Outlines 90-Day Strategic Review Under Strict Investor Disclaimers
Jun 9, 2026
Genetic Signatures Ltd. has released an investor presentation outlining a 90-day strategic review designed to position the company for growth. The board-approved materials emphasise that the presentation is informational only and proprietary, rein...
Genetic Signatures Unveils Post-Review Strategy Ahead of Investor Webinar
Jun 8, 2026
Genetic Signatures will host an investor webinar on 10 June 2026 at 10:00am AEST, where CEO Maria Halasz will present findings from a 90-day review of the company’s operations, market position, product strategy and organisational structure. ...
Genetic Signatures Announces Departure of Director Neil Gunn
May 8, 2026
Genetic Signatures Limited has announced that Dr Neil Gunn has ceased to be a director of the company as of 8 May 2026. At the time of his departure, Dr Gunn held 750,000 options as a registered holder, with no additional indirect interests or con...
Genetic Signatures Reshapes Board to Support Leaner Strategy
May 8, 2026
Genetic Signatures Limited has reorganised its board to streamline governance and sharpen its focus on strategic priorities, as the company transitions to a leaner, outsourced business model. The changes include Anne Lockwood ending her role as in...
Genetic Signatures Quantifies Revenue Impact of Danish Supply Deal
Apr 15, 2026
Genetic Signatures has detailed the expected impact of its newly announced Danish supply agreement with Hvidore, indicating that over a full year the contract should contribute around 6% of the company’s current sales. This estimate is based...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.